The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.
 
Amin Nassar
No Relationships to Disclose
 
Sarah Abou Alaiwi
No Relationships to Disclose
 
Talal El Zarif
No Relationships to Disclose
 
Ryan Austin Denu
No Relationships to Disclose
 
Salim S. Hayek
No Relationships to Disclose
 
Rachel S Goodman
Research Funding - Burroughs Wellcome Fund; Scripps Health
 
Rachel Woodford
No Relationships to Disclose
 
Tomas G. Neilan
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; C4 Therapeutics; CRC Oncology; Intrinsic Imaging; Parexel; Roche/Genentech; Sanofi
Research Funding - AstraZeneca; Bristol Myers Squibb Foundation
 
Tarek Haykal
No Relationships to Disclose
 
Yuji Kojima
No Relationships to Disclose
 
Alexandra Trevino
No Relationships to Disclose
 
Gavin Hui
No Relationships to Disclose
 
Ankita Tandon
No Relationships to Disclose
 
Edward El-Am
No Relationships to Disclose
 
Arjun Mittra
Stock and Other Ownership Interests - Merck (I)
 
Javier Baena
Honoraria - AstraZeneca Spain; AstraZeneca Spain; Bristol-Myers Squibb/Pfizer
Consulting or Advisory Role - AstraZeneca Spain; Roche; Roche
Expert Testimony - Roche
Travel, Accommodations, Expenses - MSD; MSD
 
Arrush Choudhary
No Relationships to Disclose
 
Shirly Grynberg
No Relationships to Disclose
 
Toni K. Choueiri
Stock and Other Ownership Interests - Curesponse; Osel; Pionyr; Precede Bio; Tempest Therapeutics
Honoraria - Honoraria and Advisory/Consultancy are same
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Abdul Rafeh Naqash
No Relationships to Disclose